These Analysts Slash Their Forecasts On Altimmune Following Q2 Results

Financial Performance - Altimmune, Inc. reported a quarterly loss of 27 cents per share, which was better than market estimates of a loss of 32 cents per share [1] - The company's quarterly sales amounted to $5.000K [1] Clinical Development - Pemvidutide showed rapid and robust MASH effects, significant weight loss, and impressive safety and tolerability in the recent IMPACT Phase 2b trial [2] - The company is preparing for an End-of-Phase 2 Meeting with the FDA, which will facilitate the transition to Phase 3 development [2] - Full 48-week data is expected to be reported in the fourth quarter, with further updates anticipated as pemvidutide advances [2] Stock Performance and Analyst Ratings - Following the earnings announcement, Altimmune shares increased by 5.7%, trading at $3.8250 [2] - B. Riley Securities analyst Mayank Mamtani maintained a Buy rating but lowered the price target from $20 to $18 [5] - UBS analyst Eliana Merle also maintained a Buy rating, reducing the price target from $26 to $24 [5] - HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating with a maintained price target of $12 [5]